FDAnews
www.fdanews.com/articles/205340-bforcure-gets-ce-ivd-mark-for-covid-19-test

BforCure Gets CE-IVD Mark for COVID-19 Test

November 15, 2021

BforCure has been granted a CE-IVD mark for its Bfast SARS-CoV-2 RT-PCT kit, a COVID-19 test.

BFast SARS-CoV2 is a reverse transcriptase real-time PCR triplex kit intended to diagnose SARS-CoV2, the virus that causes COVID-19, based on samples from nasopharyngeal swabs, according to the website of the France-based company. The kit is optimized for use on the company’s Chronos Dx thermocycler.

The test does not need to perform RNA extraction and provides results within 14 minutes. Each kit contains 25 tests packaged in 25 single-test tubes adapted for decentralized, near-patient testing use.

View today's stories